Adenovirus vector green light

  • 10:09

Immunicum AB (publ) today announced that the University Hospital in Uppsala has received clearance to initiate a clinical study in patients with neuroendocrine tumors with the Company’s genetically modified adenovirus vector.

Read pressrelease – Immunicum’s adenovirus technology gets green light for clinical study.

Deprecated: Theme without comments.php is deprecated since version 3.0.0 with no alternative available. Please include a comments.php template in your theme. in /home/i/immunicu/www/wp-includes/functions.php on line 4977

Comments are closed.